Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

Journal of Immunological Methods

Volumn 418, Issue , 2015, Pages 29-38

  Bloem, Karien ^a,b,c   van Leeuwen, Astrid ^c   Verbeek, Gerrit ^c   Nurmohamed, Michael T ^d   Wolbink, Gerrit Jan ^a,b,d   van der Kleij, Desiree ^c   Rispens, Theo ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Sanquin Diagnostiek   (Netherlands)

^d Jan Van Breemen Research Institute/Reade   (Netherlands)

Author keywords

Adalimumab; Anti drug antibodies (ADA); Drug interference; Drug tolerant assay; Electrochemoluminescence; Radioimmunoassay

Indexed keywords

ADALIMUMAB; ANTIIDIOTYPIC ANTIBODY; DRUG ANTIBODY; ANTIBODY; ANTIGEN; MONOCLONAL ANTIBODY;

ACID DISSOCIATION RADIOIMMUNOASSAY; ANTIBODY PRODUCTION; ANTIGEN BINDING TEST; ARTICLE; DRUG DETERMINATION; DRUG TOLERANCE; ELECTROCHEMOLUMINESCENCE BASED ASSAY; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PH SHIFT ANTI IDIOTYPE ANTIGEN BINDING TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TEMPERATURE SHIFT RADIOIMMUNOASSAY; ANTIGEN ANTIBODY REACTION; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; RADIOIMMUNOASSAY;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG TOLERANCE; HUMANS; RADIOIMMUNOASSAY;

EID: 84930341194     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.01.007     Document Type: Article

References (41)

1. Allez, M., Karmiris, K., Louis, E., Van Asche, G., Ben-Horin, S., Klein, A., Van der Woude, J., Baert, F., Eliakim, R., Katsanos, K., Brynskov, J., Steinwurz, F., Danese, S., Vermeire, S., Teillaud, J.L., Lémann, M., Chowers, Y., Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns Colitis., 4, 2010, 355.
2. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., Rutgeerts, P., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med., 348, 2003, 601.
3. Baert, F., Drobne, D., Gils, A., Vande Casteele, N., Hauenstein, S., Singh, S., Lockton, S., Rutgeerts, P., Vermeire, S., Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin. Gastroenterol. Hepatol., 12, 2014, 1474.
4. Baert, F., Vande Casteele, N., Tops, S., Noman, M., Van Asche, G., Rutgeerts, P., Gils, A., Vermeire, S., Ferrante, M., Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment. Pharmacol. Ther., 40, 2014, 1324.
5. Bartelds, G.M., Wijbrandts, C.A., Nurmohamed, M.T., Stapel, S., Lems, W.F., Aarden, L., Dijkmans, B.A., Tak, P.P., Wolbink, G.J., Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis., 66, 2007, 921.
6. Bartelds, G.M., Krieckaert, C.L., Nurmohamed, M.T., van Schouwenburg, P.A., Lems, W.F., Twisk, J.W., Dijkmans, B.A., Aarden, L., Wolbink, G.J., Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA, 305, 2011, 1460.
7. Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M.C., Saxne, T., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum., 54, 2006, 3782.
8. Bourdage, J.S., Cook, C.A., Farrington, D.L., Chain, J.S., Konrad, R.J., An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods, 327, 2007, 10.
9. Ducourau, E., Ternant, D., Lequerre, T., Fuzibet, P., Le Loët, X., Watier, H., Goupille, P., Paintaud, G., Vittecoq, O., Mulleman, D., Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann. Rheum. Dis., 73, 2014, 1428.
10. Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet, 344, 1994, 1105.
11. Garces, S., Demengeot, J., Benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis., 72, 2013, 1947.
12. Hart, M.H., de Vrieze, H., Wouters, D., Wolbink, G.J., Killestein, J., de Groot, E.R., Aarden, L.A., Rispens, T., Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods, 372, 2011, 196.
13. Krieckaert, C., Rispens, T., Wolbink, G., Immunogenicity of biological therapeutics: from assay to patient. Curr. Opin. Rheumatol., 24, 2012, 306.
14. Llinares-Tello, F., Rosas-Gomez de Salazar, J., Senabre-Gallego, J.M., Santos-Soler, G., Santos-Ramirez, C., Salas-Heredia, E., Barber-Valles, X., Molina-Garcia, J., Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol. Int., 34, 2014, 1701.
15. Lofgren, J.A., Wala, I., Koren, E., Swanson, S.J., Jing, S., Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods, 308, 2006, 101.
16. Lofgren, J.A., Dhandapani, S., Pennucci, J.J., Abbott, C.M., Mytych, D.T., Kaliyaperumal, A., Swanson, S.J., Mullenix, M.C., Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol., 178, 2007, 7467.
17. Nechansky, A., HAHA—nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J. Pharm. Biomed. Anal., 51, 2010, 252.
18. Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz Del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., Balsa, A., Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford), 50, 2011, 1445.
19. Patton, A., Mullenix, M.C., Swanson, S.J., Koren, E., An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods, 304, 2005, 189.
20. Plasencia, C., Pascual-Salcedo, D., Alcocer, P., Bonilla, M.G., Villalba, A., Peiteado, D., Arribas, F., Diez, J., Lopez-Casla, M.T., Martin-Mola, E., Balsa, A., The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab. Ann. Rheum. Dis., 72, 2013, 1888.
21. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., Phillips, J.T., Lublin, F.D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 354, 2006, 899.
22. Pouw, M.F., Krieckaert, C.L., Nurmohamed, M.T., van der Kleij, D., Aarden, L., Rispens, T., Wolbink, G., Key findings towards optimising adalimumab treatment: the concentration–effect curve. Ann. Rheum. Dis., 2013, 10.1136/annrheumdis-2013-204172.
23. Radstake, T.R., Svenson, M., Eijsbouts, A.M., van den Hoogen, F.H., Enevold, C., van Riel, P.L., Bendtzen, K., Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis., 68, 2009, 1739.
24. Rispens, T., de Vrieze, H., de Groot, E., Wouters, D., Stapel, S., Wolbink, G.J., Aarden, L.A., Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods, 375, 2012, 93.
25. Rispens, T., Hart, M.H., Ooijevaar-de Heer, P., van Leeuwen, A., Vennegoor, A., Killestein, J., Wolbink, G.J., van der Kleij, D., Drug interference in immunogenicity assays depends on valency. J. Pharm. Biomed. Anal., 85, 2013, 179.
26. Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., Kromminga, A., Immunogenicity of rituximab in patients with severe pemphigus. Clin. Immunol., 132, 2009, 334.
27. Sickert, D., Kroeger, K., Zickler, C., Chokote, E., Winkler, B., Grenet, J.M., Legay, F., Zaar, A., Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J. Immunol. Methods, 334, 2008, 29.
28. Tatarewicz, S.M., Mytych, D.T., Manning, M.S., Swanson, S.J., Moxness, M.S., Chirmule, N., Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis, 6, 2014, 1509.
29. van Schie, K.A., Hart, M.H., de Groot, E.R., Kruithof, S., Aarden, L.A., Wolbink, G.J., Rispens, T., The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann. Rheum. Dis., 74, 2015, 311.
30. van Schouwenburg, P.A., Bartelds, G.M., Hart, M.H., Aarden, L., Wolbink, G.J., Wouters, D., A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods, 362, 2010, 82.
31. van Schouwenburg, P.A., Krieckaert, C.L., Rispens, T., Aarden, L., Wolbink, G.J., Wouters, D., Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann. Rheum. Dis., 72, 2013, 1680.
32. van Schouwenburg, P.A., Rispens, T., Wolbink, G.J., Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol., 9, 2013, 164.
33. van Schouwenburg, P.A., Kruithof, S., Votsmeier, C., van Schie, K., Hart, M.H., de Jong, R.N., van Buren, E.E., van Ham, M., Aarden, L., Wolbink, G., Wouters, D., Rispens, T., Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J. Biol. Chem., 289, 2014, 34482.
34. Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., Vermeire, S., Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol., 108, 2013, 962.
35. Vande Casteele, N., Feagan, B.G., Gils, A., Vermeire, S., Khanna, R., Sandborn, W.J., Levesque, B.G., Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr. Gastroenterol. Rep., 16, 2014, 378.
36. Vennegoor, A., Rispens, T., Strijbis, E.M., Seewann, A., Uitdehaag, B.M., Balk, L.J., Barkhof, F., Polman, C.H., Wolbink, G., Killestein, J., Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult. Scler., 19, 2013, 593.
37. Vincent, F.B., Morand, E.F., Murphy, K., Mackay, F., Mariette, X., Marcelli, C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann. Rheum. Dis., 72, 2013, 165.
38. Wang, S.L., Ohrmund, L., Hauenstein, S., Salbato, J., Reddy, R., Monk, P., Lockton, S., Ling, N., Singh, S., Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J. Immunol. Methods, 382, 2012, 177.
39. Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., Teoh, L.A., Fischkoff, S.A., Chartash, E.K., Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum., 48, 2003, 35.
40. Wolbink, G.J., Vis, M., Lems, W., Voskuyl, A.E., de Groot, E., Nurmohamed, M.T., Stapel, S., Tak, P.P., Aarden, L., Dijkmans, B., Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum., 54, 2006, 711.
41. Zhong, Z.D., Dinnogen, S., Hokom, M., Ray, C., Weinreich, D., Swanson, S.J., Chirmule, N., Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods, 355, 2010, 21.